Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...

Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...

HIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...

Twice-a-year-PReP will only fulfill its potential if Medicaid takes decisive action to ensure it is accessible to the ...

Both lenacapvir and Truvada were generally well-tolerated and Gilead said there were no significant or new safety concerns ..

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company wi ...

Young people living with HIV play a critical role in the fight against AIDS in communities. They offer support and share ...

Black gay and bisexual men made up about 38% of the estimated 37,981 new HIV diagnoses in the U.S. in 2022. The Centers for ...

In the 80′s, contracting HIV was considered a death sentence. In the 90′s, HIV was the number one cause of death among ...

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has raised alarm over the increasing incidence of HIV among young ...

While new HIV infections among children aged 0-14 years and adolescents aged 15-19 years declined since 2000, progress has ...